EBiSC news & events
26.-29. June 2019 : Meet EBiSC2 at the ISSCR 2019 Annual Meeting in Los Angeles!
For the fifth consecutive year, EBiSC2 representatives will participate in the Annual Meeting of the International Society for Stem Cell Research taking place from 26 to 29 June 2019 in Los Angeles / USA.
- Talk to EBiSC2 representatives at stand no. 728 to explore the EBiSC catalogue (https://cells.ebisc.org) and progress your research through use of EBiSC services
- Join the EBiSC2 Meet-Up Hub no. 2 in the Exhibit Hall on Thursday, 27 June from 12:15-13:00 and learn how EBiSC2 can facilitate your iPSC research projects and simplify hiPSC line deposition
- Learn how you can easily order and receive your lines from the EBiSC catalogue or share your hiPSC lines with EBiSC
- Discover how EBiSC2 will increase its product portfolio tailored to market demands
- Engage in one-on-one discussions with EBiSC2 researchers during the Poster Sessions on 26 June at 19:30 and on 28 June at 18:00 and 19:00
- Feedback to EBiSC2 on how we can help you with your research and help us continue building a bank which meets your needs
11. March 2019: EBiSC2 – The European Bank for induced pluripotent Stem Cells launches a second project phase
EBiSC2 – The European Bank for induced pluripotent Stem Cells launches a second project phase to become a self-sustainable repository for human induced pluripotent stem cells (hiPSC), extend the existing cell catalogue, and offer additional hiPSC-related services.
EBiSC2 will secure long-term access to well characterised and quality-controlled hiPSCs for academic and commercial researchers worldwide, continuing to support R&D activities such as disease modelling and drug discovery.
Brussels, 11th March 2019 (12:00 CET)
EBiSC2 builds on the achievements of the European Bank for hiPSCs (EBiSC, www.ebisc.eu), giving academic and commercial researchers access to high quality hiPSCs from diverse disease and genetic backgrounds (cells.ebisc.org). Supported by the Innovative Medicines Initiative 2 (IMI2 JU), a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA), key partners of the initial EBiSC project are joining forces to build on EBiSC's existing assets and establish EBiSC2 as a self-sustainable central bank for hiPSC lines, focused on satisfying user requirements.
Launched on 1st March 2019 and focussed on the needs of the research community and scientific excellence, EBiSC2 will continue to distribute disease-relevant and high quality hiPSCs with freedom to operate for research, along with comprehensive datasets. Additional services such as bulk production of hiPSCs and delivery of pre-differentiated cell populations will be established to facilitate the use of hiPSC in research.
EBiSC2 aims to collaborate with other ongoing or future iPSC programmes in an effort to continue serving as a central hub for collection, banking, quality control and distribution of hiPSC lines, resulting in secured access for the research community to assets generated with public funds within these projects. Building on EBiSC's established clinical network, EBiSC2 will also progress clinical engagement to support collection and appropriate management of disease-relevant patient data to support disease modelling and drug discovery activities.
Prof. Dr. Heiko Zimmermann, head of the Fraunhofer Institute for Biomedical Engineering IBMT (Germany), the EBiSC2 Project Coordinator, states: "Requirements from hiPSC users in academia and industry are ever evolving. To meet this demand, the EBiSC2 cell catalogue will be constantly enriched through on-demand generation of new hiPSC lines, including gene-edited lines and isogenic controls, hiPSC-derived progenitor cells and continued deposition of hiPSC cohorts generated in external research projects. We will distribute cell lines and develop a range of additional cell services, for instance through the supply of screening panels of disease-relevant and control hiPSC lines in ready-to-use-formats, to maximise the value of these resources, whilst reducing operational costs through state-of-the-art upscaling and automation."
Dr. Andreas Ebneth, Scientific Director of Janssen Pharmaceutica NV's Neuroscience Therapeutic Area (Belgium), the EBiSC2 Project Leader, comments: "Proof-of-concept studies will be performed jointly by academic and pharmaceutical partners to demonstrate the reliability and robustness of the EBiSC lines for disease modelling and screening. The extensive data generated within those studies will further enrich the EBiSC2 catalogue. Long-term sustainability of the EBiSC2 bank will guarantee continuous access to an important high-quality, disease-relevant hiPSC resource for academic and commercial researchers worldwide. EBiSC2 may thus support future advances in the field of hiPSC-based disease research with the ultimate goal to discover and develop new drugs for improving the health and lives of people internationally."
(For the full press release: Click here)
Partner organisations involved in EBiSC2:
Research organisations, universities, public bodies:
- Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. - Institut für Biomedizinische Technik (IBMT), Germany
- Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. - Fraunhofer UK Research Ltd, United Kingdom
- Charité - Universitätsmedizin Berlin, Germany
- Department of Health and Social Care, European Collection of Authenticated Cell Cultures, United Kingdom
- Bioneer A/S, Denmark
- Katholieke Universiteit Leuven, Stem Cell Institute Leuven, Belgium
- ARTTIC SAS, France
Pharmaceutical companies (EFPIA members):
- Janssen Pharmaceutica NV, Belgium
- Bayer AG, Germany
- Eli Lilly & Co. Ltd., United Kingdom
- Lundbeck A/S, Denmark
- Novo Nordisk A/S, Denmark
- UCB Biopharma SPRL, Belgium
- Pfizer Ltd, United Kingdom
- Takeda Development Centre Europe Ltd., United Kingdom
- FUJIFILM Cellular Dynamics, Inc., United States
- Institut de Recherches Servier, France
EBiSC2 is supported by the IMI2 JU with 4.6 million Euro and further by the EFPIA members with 4.3 million Euro. The project runs over three and a half years and will end on 31st August 2022.
Access to the public EBiSC Catalogue: https://cells.ebisc.org
08. January 2019: New EBiSC related manuscript published in Stem Cell Research
A new EBiSC related manuscript led by the EBiSC partner Bioneer and entitled "Generation of a set of isogenic, gene-edited iPSC lines homozygous for all main APOE variants and an APOE knock-out line" has been published in Stem Cell Research in January 2019.
13. April 2018: The EBiSC Final Report is now available
The final Executive Summary of the EBiSC project has now been published providing an overview of the experience and achievements made in the fours years of project lifetime.
18. January 2018: Watch the new EBiSC FILM promoting the EU central non-profit iPSC repository !
The EBiSC film is now avaiable !
Learn all about the "European Bank for induced Pluripotent Stem Cells" distributing iPSC lines worldwide. Check out the cell line catalogue, quality control standards and how to order iPSC lines from EBiSC. The EBiCS film can be viewed on YouTube.
15. December 2017: EBiSC talks from the Final Workshop now online !
The EBiSC Final Workshop has successfully taken place on 2-3 November 2017 at Fraunhofer Forum in Berlin. If you were unable to attend the event or you would like to listen again to one of the presentations given by our EBiSC project partners, check out the seven new EBiSC project videos available in the EBiSC documentation archive.
06. November 2017: EBiSC Webinar "iPSCs: The future of disease research" on 9 Nov. (16:00 GMT)
The development of human iPSC technology offers researchers the ability to more accurately generate physiologically relevant models of disease and normal tissues in the laboratory. Advances in iPSC generation have allowed many laboratories to make their own cell lines; however, researchers rarely have the resources needed to establish stocks, undertake quality control and share their own de novo iPSC cell lines with other laboratories. A pre-existing and established iPSC collection therefore allows iPSC researchers to obtain "off the shelf" access to a large, robust and reliable supply of iPS cell lines that represent diverse donor to donor variability and which include disease status normal controls and gene edited cell lines. iPSCs from ECACC are standardized and quality controlled and have the benefit of coming from a trusted and internationally recognized collection with worldwide distribution.
You will learn about the:
- History and development of the EBiSC iPSC project
- Variety of diseases represented in the collection
- Applications of iPS cell lines
- Availability of lines and how to access them.
Who Should Attend?
- Stem cell researchers
- Researchers working on disease modelling and pre-clinical research
- Scientists interested in improving their cell models
- Cell Biologists
- Molecular Biologists
- Toxicologists and Pharmacologists
The webinar will be given by Dr. Sharon Bahia, product and distribution manager at ECACC, the European Collection of Authenticated Cell Cultures.
Register NOW for free !
04. October 2017: Joint EBiSC-StemBANCC paper published focusing on the new European General Data Protection Regulations
The paper "The European General Data Protection Regulation: challenges and considerations for iPSC researchers and biobanks" jointly prepared by the IMI projects, EBiSC and StemBANCC, has been published in the journal Regenerative Medicine on October 4th, 2017.
Increasingly, human induced pluripotent stem cells (iPSC) and their associated genetic and clinical information, are being used in a wide range of applications, with large biobanks being established to support and increase their scientific use. The new European General Data Protection Regulations, which comes into effect in 2018, will have implications for biobanks that generate, store and allow research access to iPSC. This paper describes some of the challenges that iPSC biobanks face and suggests some points for the development of appropriate governance structures to address these new requirements. These suggestions also have implications for iPSC research in general.
To read the full paper, please click here.
16. June 2017: Next EBiSC Workshop on 2-3 November 2017 in Berlin
The EBiSC consortium invites you to the Workshop on "Scalability of the iPSC technology for future drug discovery & therapy" which will take place on 2-3 November 2017 at Fraunhofer-Forum in Berlin.
The workshop aims at disseminating the learning from the establishment of EBiSC and address perspectives on stem cell applications over the next five years. We are expecting a large audience composed of industry representatives considering stem cell investment, stem cell researchers from academia and SMEs as well as representatives of government policy group, charities and trade organisations supporting stem cell research.
To view the full programme, download the EBiSC Workshop Flyer.
Please fill in the Registration Form until 27 October 2017. Limited places available.
For further questions, please contact email@example.com.
14. June 2017: Meet EBiSC at the ISSCR 2017 Annual Meeting in Boston !
For the third consecutive year, EBiSC representatives will participate in the Annual Meeting of the International Society for Stem Cell Research taking place from 14 to 17 June 2017 in Boston / USA.
- Visit the ECACC stand (no. 844) in the exhibition hall to explore the EBiSC catalogue (https://cells.ebisc.org)
- Talk to our colleagues to learn how EBiSC can facilitate your current and future iPSC research projects and
- Use the opportunity to get answers to all your questions related to the EBiSC catalogue and how you can easily order and receive our iPSC lines.
15. May 2017: Training Video on "Cryopreservation" - now online!
Learn more about how to cryopreserve EBiSC iPS cells ! The new training tool composed of a video and test questionnaire is now available in the EBiSC virtual Training Library.
To view the video, you just need to login. If you have not yet registered for using the Training Library, just fill in the registration form and confirm your email address. You can then watch the 5 different video trainings on iPSC Standard Operating Procedures which are now available in the EBiSC virtual Training Library. Test your new knowledge at the end of each training and answer the few test questions proposed under the training videos.
EBiSC is looking forward to receiving your feedback!
25. April 2017: EBiSC organised the 4th General Assembly meeting
On the 24-25 April 2017, the EBiSC consortium met in Egmond aan Zee (The Netherlands) to present latest project results and discuss on-going and forthcoming activities.
12. January 2017: Tell EBiSC your needs for iPSC in your research projects
EBiSC is currently carrying out a survey about the use of induced pluripotent Stem Cell (iPSC) lines in research. If you use or plan to use iPSC in your organisation, we would be very grateful for your contriubtion to the survey, which will take less than 15 minutes of your time. Your responses will be kept confidential and can be provided anonymously if you wish.
Your responses will help EBiSC to provide the pluripotent stem cell research community with improved products and services. To thank you for your time and input, you can also enter a prize draw with the chance to win a free cell line of your choice from the EBiSC catalogue (please note shipping costs are not included).
Please forward the link of the survey to any of your colleagues who might also be interested in taking part. If you have any questions about the research, or any problems with the survey pages, please use the contact form on www.ebisc.eu.
01. October 2016: 23.-25. November 2016 EBiSC training course on differentiation of iPS cells into neuron and cardiomyocyte lineages
The next EBiSC training course on « Differentiation of iPS cells into neuron and cardiomyocyte lineages » will take place from 23 to 25 November 2016 in Midlothian, United Kingdom. The course will be run in the high quality EBiSC central stem cell laboratory facilities at Roslin BioCentre.
This event brings together the extensive expertise of the EBiSC project partnership from across Europe. It provides hands on training and workshop activities in stem cell technology relating to the culture and differentiation of pluripotent stem cell lines into cardiac and neural cell types and their functional characterisation.
Dates: Wednesday 23 November 2016 - Friday 25 November 2016
Location: Roslin BioCentre, Wallace Building, Roslin EH25 9PP
For further information contact firstname.lastname@example.org.
18.-21. October 2016 : EBiSC at the Stem Cells & Gene Therapy Symposium organized by ESGCT & ISSCR
EBiSC will participate in the Stem Cells & Gene Therapy Symposium organized by ESGCT & ISSCR on 18-21 October in Florence: “Changing the Face of Modern Medicine: Stem Cells & Gene Therapy”. Meet EBiSC representatives at stand no. 11 !
08. August 2016: EBiSC supports the research on bipolar disorder
University of Edinburgh annonces today that iPSC lines generated from patients with bipolar disorder will be expanded and banked by Roslin Cell Sciences and made available for research to academic and commercial researchers worldwide through EBiSC.
01. August 2016: EBiSC launchs a Call for Tender for assessing the market for research grade iPSC lines
EBiSC is looking for a subcontractor having comprehensive expertise, experience and competencies in gathering global data on the research use of the iPSC technology, iPS banks and their use and overall market. The call will be closed on Friday, 26 August at 17:00 Brussel's time.
09.-12. July 2016 : EBiSC Catalogue at the 24th Biennial Congress of the European Association for Cancer Research
The EBiSC partner ECACC will present the EBiSC Catalogue at 24th Biennial Congress of the European Association for Cancer Research on 9-12 July in Manchester.
22.-25. June 2016 : Meet EBiSC at the ISSCR 2016 Annual Meeting !
On Wednesday 22 June 2016 (09:00-12:00), EBiSC will organise a Focus Session at this year’s Annual Meeting of the International Society of Stem Cell Research (ISSRC). We will share experiences about establishing an international iPSC bank and standardized work flows for tissue procurement, high quality generation, characterization, expansion, cryopreservation of iPSC and distribution and the challenges about making iPSC lines internationally available for research work.
On Thursday at 12:15-13:00, you can meet EBiSC representatives face-to-face at the Meet-up Hub 2 in the Exhibition Hall to get more information about the EBiSC iPSC catalogue and discuss your research needs and opportunities to engage with EBiSC.
15. June 2015: EBiSC catalogue growing with additionnal 63 lines available
A total of 147 of cell lines are now available on cells.ebisc.org.
15. June 2015: Follow EBiSC on twitter!
Follow EBiSC on twitter and get all latest updates about the catalogue, events & news of the bank!
23.-26. May 2016 : Cellular Reprogramming and Culture of hiPSCs: a practical training course and UK Stem Cell Bank workshop on gene-editing
A collaboration between world-leading stem cell resource centres
REGISTRATION OPEN |Book before 5th March
The EBiSC Derivation and culture of hiPSCs practical training course and workshop will take place on 23rd – 25th May 2016 at the University of Hertfordshire, UK (http://www.herts.ac.uk/).
The course will comprise lectures and ‘wet lab’ sessions from the 23rd to 25th May at the University of Hertfordshire.
This will be followed by a Technical Forum, on the 26th May, to be held at the UK Stem Cell Bank. The Technical Forum will cover gene editing of hESCs and iPSCs.
For any questions on the course please contact Orla O’Shea email@example.com
To reserve your place, please fill out the relevant registration form.
Special accommodation rate for the EBiSC training participants has been secured with the Ramada Hatfield Hotel, St Albans Road West, Hatfield, Hertfordshire, AL10 9RH
As places are limited, to avoid disappointment, please book before 5th March.
23. March 2016: Launch of the European iPSC Bank
On 23rd March, EBiSC officially announces the public launch of induced Pluripotent Stem Cells (iPSCs) on-line catalogue. Access to the entire Press-Release here.
14.-17. December 2015 : Derivation and Culture of hiPSCs Workshop, Hinxton-UK
This 4-day workshop will include lectures and laboratory-based training sessions covering current theory and best practices with regard to derivation and culture of hiPSCs.
Application deadline: 25 September 2015.
More info here.
16. October 2015: EBiSC in consortia-pedia catalogue
EBiSC profile is now available in the Consortia-pedia Catalogue, a searchable, online resource featuring profiles of around 400 international medical research consortia presenting information about its mission, structure, partners, financing models and data sharing practices.
23. June 2015: Fill out our questionnaire !
We would like to know what cell lines you wish to see included in the EBiSC iPSC catalogue to support your research now and in the future.
Thank you for filling out our questionnaire !
We appreciate your input.
22. May 2015: EBiSC to help UCL make new iPSC lines
University College London (UCL) holds a valuable collection of skin cells from patients with neurodegenerative diseases such as Alzheimer’s. EBiSC is making new iPSC lines from some of these precious UCL samples to allow researchers to better understand disease mechanisms.
27. April 2015: Second EBiSC General Assembly Meeting
The General Assembly Meeting of the EBiSC project took place on 23-24 April 2015 at Granta Park (UK). EBiSC representatives from the academic institutions and EFPIA participated in this second annual project meeting. The consortium was pleased to welcome two members of the Scientific Advisory Board, Prof. Hideyuki Okano (Keio University, Japan) and Prof. Peter Andrews (University of Sheffield, UK), as well as Dr. Fatiha Sadallah from the IMI JU. The successful meeting was combined with visits of the EBiSC Central Facility at the Babraham Research Center.
22. April 2015: Opening of the Fraunhofer IBMT enabling lab in the EBiSC central processing laboratories, Babraham Research Campus, Cambridge, UK
Fraunhofer IBMT installed a cell culture lab at the central facility site which is in operation now. It is equipped with automation technologies for automated pipetting, cell expansion and freezing to increase efficiency of the manual processes along with reduced time and costs, enabling more cost effective operations. The Fraunhofer IBMT UK lab is led by Dr. Erwin Gorjup.
31. March 2015: Sistemic to miRNA profile EBiSC Hot Start lines
Using the initial collection of 64 Hot Start iPSC lines, Sistemic Ltd, a leading Scottish based SME with proprietary bioinformatics platforms, will analyse each line’s miRNA profile. This will then be compared with a database of known profiles from human pluripotent stem cell lines to seek for common associations and patterns of expression predictive of differentiative potential. It is hoped that these experiments, if successful and with further validation, will enable EBiSC to develop more efficient Quality Control analysis for the cell lines.
24. October 2014: Installation of the mirror storage bank at Fraunhofer IBMT, Sulzbach, Germany
The Fraunhofer IBMT established a mirror storage facility capable of holding a reserve stock of the entire EBiSC cell line catalogue. The facility is equipped with a workbench for freezing and handling of the cell vials, three storage towers with pick-and-place-robots and an automated rail system for transport of the cell vials (Askion C-Line system). The storage system enables a closed cooling chain performance and the traceability as well as the management of the vials. The storage capacity of the mirror bank is 60 000 vials. The facility is in operation since October 2014.
09. October 2014: Alpha synuclein triplication lines to come into EBiSC
Tilo’s alpha synuclein triplication lines are derived from a donor with early onset Parkinson’s disease. In an exciting development, his lab has also genetically edited the α-syn triplication lines to partially and completely remove the additional copies so give a control line with the same background genetics as the disease line – an isogenic control. Initially, the lines will be for use by EBiSC consortium partners only, but following publication, the lines will be made generally available. If your lab is interested in these lines then please contact EBiSC to find out more.
30. September 2014: The “Hot Start” phase of the EBiSC Foundational Collection has started
with the arrival of the first iPSC lines from Newcastle University and the Universitätsklinikum Bonn. These will be joined by up to 60 additional Hot Start lines from our 8 iPSC centres.
27. June 2014: EBiSC Workshop for further engagement of clinicians, Copenhagen / Denmark (Lundbeck)
The first EBiSC workshop aimed at supporting further engagement of clinicians in Denmark so as to boost interactions between the EBiSC iPSC Centres and clinical centres in Denmark.
26.-30. May 2014 : EBiSC HiPSC training course at the University of Hertfordshire, UK
This practical training course and workshop in the derivation and culture of hiPSCs represents collaboration between leading international stem cell resource centres including the EBiSC consortium.
21. May 2014: EBiSC presentation at the IMI Stakeholder Forum in Brussels, Belgium
This event presenting IMI’s latest results as well as current activities and plans was the opportunity to showcase the EBiSC project to policy-makers, industry decision-makers, SMEs, patient groups, academia and researchers. For more information: click here.
Watch the presentation of Aidan Courtney (Roslin Cells) on YouTube!
All further relevant events
10. May 2016: Roslin stem cell companies combine to create Censo Biotechnologies group
The merger was announced today of Roslin Cell Sciences and Roslin Cellab, two companies previously created as spin outs from the Roslin Institute and both focussed on using stem cells to discover new drugs. Following the merger, the parent company has been renamed Censo Biotechnologies Ltd with Roslin Cell Sciences Ltd continuing to trade as a wholly owned subsidiary. Read more >>
26.-27. October 2015 : ToxBank Public Forum, London-UK
Come and visit us at the forum where EBiSC will present a session about iPSC resource for disease studies.
This forum will discuss the results of the recent research and development of alternative testing methods aimed to replace animal testing, and the potential impact this work has on our society.
Check the programme and register here.
23.-26. October 2014 : 23rd Annual ESCGT Congress in The Hague, The Netherlands
The EBiSC Consortium is very pleased to support the sponsorship of Prof Shinya Yamanaka’s talk at the 23rd Annual European Society of Gene & Cell Therapy (ESGCT).
More information: www.esgct.eu
18.-21. June 2014 : ISSCR Annual Meeting in Vancouver, Canada
The International Society for Stem Cell Research (ISSCR) organised its 12th annual meeting gathering scientists, clinicians, educators and industry professionals with a broad program around stem cell research.
The EBiSC Coordinator Tim Allsopp is currently chair of the Industry Committee of the society and has recently been elected as Industry representative to the Society Executive Committee, serving from June 2014 for 3 years.
More information: www.isscr.org/home/2014annualmeeting
12. June 2014: TERMIS 2014 EU in Genova, Italy
This conference aims at presenting the latest scientific and clinical innovations in the field of tissue engineering and regenerative medicine. The EBiSC project was presented by our EBiSC partner, the University College London.
More information: www.termis.org/eu2014/
02.-03. June 2014 : 15th Annual Drug Discovery Leaders Summit in Geneva, Switzerland
For this 15th edition, the EBiSC project has been presented to pharmaceutical organisations representatives as well as to biotech companies and academic institutions.
More information: www.drugdiscovery-summit.com
28. May 2014: Horizons in Human Cells in Edinburgh, UK
This conference exploring the interface of science, engineering, medicine and society in human cellular discovery and therapy gave the opportunity to Fraunhofer-IBMT, Roslin Cells and the University of Edinburgh to discuss non-profit iPSC banking and automated pluripotent stem cells production and processing.
Programme available here
More information: www.horizonsinhumancells.org